LOS ANGELES, CA - Patrick Soon-Shiong (Image credit: Getty Images North America via @daylife)
Abraxane, a cancer chemotherapy made by Celgene, slowed tumor growth and cut the risk of death in patients with advanced pancreatic cancer, according to results that will be presented at a conference on gastrointestinal tumors being held by the American Society of Clinical Oncology.
Patients on a combination of Abraxane and gemcitabine, another chemotherapy, lived for a median 8.5 months, compared...
Read Full Story